Navigation Links
ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
Date:3/1/2010

ClearTrial Study Costing & Optimization Service acts as an extension of a company's clinical team to deliver greater visibility and control over clinical trial costs, resources, and timelines.

Chicago, IL (PRWEB) March 1, 2010 -- ClearTrial (www.cleartrial.com), the leading provider of Clinical Trial Operations (CTO) software, today unveiled the ClearTrial Study Costing & Optimization Service (SCOS), a turn-key, cost-effective service that provides greater visibility and control over clinical trial costs, resources, and timelines for smaller biopharma companies. The ClearTrial SCOS delivers a powerful combination of proven ClearTrial software -- used by the world’s leading biopharmaceutical, clinical research, and medical device organizations each day to improve efficiency and performance in clinical operations -- and ClearTrial’s Clinical Services personnel to bring greater speed and accuracy to clinical trial planning.

"Many smaller biopharma companies lack the visibility to accurately forecast clinical trials, leading to them not understanding how much clinical trials should really cost, as well as dealing with unforeseen shifts in trial timelines," noted Andrew Grygiel, Vice President of Marketing and Product Management for ClearTrial. "We conducted an extensive pilot program of the ClearTrial Study Costing & Optimization Service, and in every case were able to identify dramatic reductions in study costs and timelines, while ensuring that the studies were still achievable."

During the ClearTrial SCOS, a ClearTrial Clinical Services Manager (CSM) -- an expert in clinical development, outsourcing, and project management -- acts as a highly experienced extension of a company's internal clinical team. The ClearTrial CSM works with that team to fully understand the study's design, objectives, and clinical assumptions, then leverages the industry intelligence and activity-based planning methodology of the ClearTrial software to generate detailed and accurate cost, resource, and timeline reports for multiple study scenarios. These scenarios enable the ClearTrial CSM and the company's team to easily perform "what-if" analyses for cutting cost, time, or both from a study. According to recent accounts by ClearTrial customers, ClearTrial costing scenarios have been proven to deliver 1–5% accuracy when benchmarked against actual study costs.

The ClearTrial Study Costing & Optimization Service also provides sponsor/CRO negotiation leverage for additional cost savings. With a comprehensive inventory of clinical assumptions backing up monthly budget estimates, and projections for unit costs, unit hours, timeline projections, cash flows and recommended resource staffing, the ClearTrial SCOS arms clinical teams with the data they need to ensure a project is getting the attention and the budget it requires.

"As the cost and timeline pressures continue to grow, organizations large and small must ensure that their clinical trial dollars are being spent as effectively as possible," stated ClearTrial CEO Mike Soenen. "We're pleased to be able to help our industry achieve this goal by introducing the ClearTrial Study Costing & Optimization Service to the market."

About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information contact:

Mike Lange
ClearTrial
+1 630.986.9800 x112

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3659584.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. ClearTrial Selected to Provide Methodologies for Accurately Forecasting and Budgeting Clinical Spend and Integrated Financial Controls at CBI Conference
2. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
3. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
4. ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development
5. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
6. ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials
7. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
8. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
9. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
10. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
11. IFDC Launches Virtual Fertilizer Research Center
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
(Date:2/18/2017)... MONTREAL , February 18, 2017 ... von intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische ... ... Biosciences Inc. heute bekanntgab, wird Dr. Yoav Peretz ... Methoden in der Entwicklung von Assays zum Nachweis intrazellulärer ...
(Date:2/18/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... , Feb. 17, 2017  If only ... tumor had a mutation-conferring resistance to chemotherapy, thousands ... genomics research has focused on finding these mutations ... even from circulating tumor DNA in blood — ... oncology therapeutics. Unfortunately, however, detecting these ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... EIT ... framework primarily aimed at the agricultural industry. Pilot studies are about to get under ... through IoT, Big Data and 5G innovations. The concept is expected to be transferred ...
Breaking Biology Technology:
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):